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Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism.
Agonists for both PPARγ and PPARγ have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to aﬀecting
glucose metabolism, PPARγ agonists also regulate lipid metabolism. In this review, we will focus on the randomized clinical trials
that directly compared the lipid eﬀects of the thiazolidinedione class of PPARγ agonists, pioglitazone and rosiglitazone, head-to-
head either as monotherapy or in combination with other lipid-altering or glucose-lowering agents
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1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) play
an important role in regulating both glucose and lipid
metabolism. Agonists for both PPARα and PPARγ have been
used to treat dyslipidemia and hyperglycemia, respectively.
In addition to aﬀecting glucose metabolism, PPARγ agonists
also regulate lipid metabolism.
The dyslipidemia of type 2 diabetes mellitus is character-
ized by elevations in serum triglycerides and increased very
low-density lipoprotein (VLDL) particle size, reduced high-
density lipoprotein (HDL) cholesterol and HDL particle
size, and the predominance of small, dense low-density
lipoprotein (LDL) particles with generally normal LDL
cholesterol. Many studies have examined the eﬀect of
improvements in glycemic control on serum lipids and
lipoproteins utilizing a variety of glucose-lowering medica-
tions [1]. These include insulin, sulfonylureas, biguanides,
thiazolidinediones, glucagon-like peptides, α-glucosidase
inhibitors, and dipeptidyl peptidase-IV inhibitors. In gen-
eral, improving glycemic control reduces serum triglycerides
and increases HDL cholesterol. Numerous studies have com-
paredtheeﬀectofthiazolidinedioneswithotheroralglucose-
lowering medications. In general, thiazolidinediones have
better overall eﬀects on lipids compared to sulfonylureas or
insulin[2,3].Inthisreview,wewillfocusontherandomized
clinical trials that directly compared the lipid eﬀects of the
thiazolidinedione class of PPARγ agonists, pioglitazone and
rosiglitazone, head to head either as monotherapy or in
combination with other lipid-altering or glucose-lowering
agents. The eﬀects of troglitazone (Rezulin), which has been
removed from the market, will not be discussed.
2. ROLE OF PPARγ IN REGULATING FATTY
ACID/TRIGLYCERIDE METABOLISM
The whole-body response to activating PPARγ is storage of
energy, as triglycerides, in adipocytes. This is accomplished
by the coordinated regulation of tissue-speciﬁc gene expres-
sion in adipocytes, liver, and cells that utilize fatty acids for
energy as well as various circulating factors that coordinate
and regulate fatty acid synthesis and utilization. Although
often only serum triglycerides are measured and monitored
in patients, serum triglycerides represent just one com-
partment within which PPARγ medications aﬀect whole-
body triglyceride/fatty acid metabolism. Serum triglycerides
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mechanism by which energy (as triglycerides) is transported
from one tissue to another (Figure 1).
In the adipocyte, both pioglitazone and rosiglitazone
increase the expression of genes associated with hydrolysis
of triglyceride-rich lipoproteins and fatty acid uptake and
storage[4,5](Figure 1).Thiazolidinedionesalsoreducefatty
acid release from adipocytes. This in turn leads to less fatty
aciddeliverytotheliverandadecreaseinhepatictriglyceride
synthesis. In addition, PPARγ medications inﬂuence secre-
tion of adipokines that aﬀect lipid and glucose metabolism.
Pioglitazoneandrosiglitazonetherapiesincreaseadiponectin
[6, 7] and decrease retinol binding protein 4 [8] and resistin
[9]. These adipokines inﬂuence lipid metabolism and insulin
sensitivity.
In the liver, PPARγ therapy is associated with changes
in expression of various genes involved in lipid metabolism
including apolipoproteins CII and CIII. Apolipoproteins CII
and CIII stimulate and inhibit lipoprotein lipase, respec-
tively. Lipoprotein lipase is the major enzyme involved
in hydrolyzing and removing triglyceride-rich lipoproteins
from the serum.
3. COMPARISON OF LIPID EFFECTS OF





Goldberg et al. [10]a n dD e e ge ta l .[ 11] compared the
eﬀects of pioglitazone and rosiglitazone in patients with
type 2 diabetes mellitus and dyslipidemia on non-lipid-
altering medications (see Table 1). After discontinuing their
glucose-lowering and lipid-altering medications, if they were
on them, patients were randomized to pioglitazone or
rosiglitazone. Patients were treated with 30mg once a day
(QD) of pioglitazone or 4mg of rosiglitazone QD for 12
weeks with a forced titration to 45mg QD and 4mg twice a
day (bid) for additional 12 weeks, respectively. Both medica-
tions reduced hemoglobin A1c (A1c), insulin resistance (as
determined by HOMA-IR), and fasting free fatty acids to a
similar extent. However, the eﬀects on fasting triglycerides
were divergent. Pioglitazone therapy was associated with
a reduction in fasting triglycerides throughout the study,
whereas rosiglitazone increased triglycerides within 4 weeks,
which then declined with time. At the end of the study,
triglycerides were decreased by 12% with pioglitazone, and
elevated by 15% in patients on rosiglitazone.
The decrease in triglycerides with pioglitazone was
associated with a decrease in large VLDL and interme-
diate density lipoproteins (IDLs), whereas the increase
in triglycerides with rosiglitazone was associated with an
increase in both large- and medium-sized VLDL and IDL
concentrations.Pioglitazonedecreasedwhereasrosiglitazone
increased apolipoprotein CIII.
Both medications raised LDL cholesterol; however, the
increase was signiﬁcantly greater with rosiglitazone com-
pared to pioglitazone (12.3% and 21.3%, resp.). Both
therapies increased the average size of LDL particles, but the
eﬀect of pioglitazone was greater than that of rosiglitazone.
Consistent with the changes in LDL cholesterol, pioglitazone
did not signiﬁcantly change apolipoprotein B levels but did
reduce LDL particle concentration. Conversely, rosiglitazone
increased both apolipoprotein B and LDL particle concen-
tration. The clinical signiﬁcance of the diﬀerence in particle
concentration is unclear although decreased LDL particle
concentration has been associated with a reduced risk for
coronary heart disease [12, 13]. Both medications raised
serum levels of lipoprotein (a).
As expected, both medications increased HDL choles-
terol and the average size of HDL particles; however theM .A .D e e ga n dM .H .T a n 3




N Duration Pioglitazone eﬀects Rosiglitazone eﬀects
Derosa et al.
[16, 17] Glimepiride 91 52 wk
↑HDL-C, apo AI
↓TC∗,L D L - C ∗,
↓TG∗,a p oB ∗, Lp(a)∗
↑TC∗,L D L - C ∗,H D L - C ,
↑TG∗, apo AI, apo B∗,
lipoprotein (a)
Goldberg et al.
[10], Deeg et al.
[11]
None 802 24 wk
↑HDL-C∗,L D L - C ∗,T C ∗
↓TG∗
↑VLDL-P, HDL-P∗,a p oA I
↓LDL-P∗, apo CIII∗
↑TG∗,H D L - C ∗,L D L - C ∗,
↑TC∗,a p oB ∗
↑VLDL-P, HDL-P∗,
LDL-P∗,a p oC I I I ∗
↓apo AI∗
Berhanu et al. [19] Statins 305 17 wk
↓TG∗,T C ∗,L D L - P ,









Derosa et al. [18]M e t f o r m i n 96 52 wk
↓TC∗,L D L - C ∗,T G ∗,a p o
B∗
↑HDL-C∗,a p oA I ∗
No signiﬁcant changes in
any lipid parameter
Berneis et al. [14]N o n e 91 2 w k ↑TC, HDL, LDL, LDL IIA∗
↓TG∗
↑TC, TG∗, HDL, LDL,
LDL-IIA
N = number of patients enrolled. Pioglitazone and rosiglitazone eﬀects are summarized as % change from baseline and listed in parentheses. (∗) indicates a
statistically signiﬁcant change from baseline. TC = total cholesterol, TG = triglycerides, LDL-C = LDL cholesterol, HDL-C = HDL cholesterol, LDL-P = LDL
particle number, HDL-P = HDL particle number, apo = apolipoprotein, AUC-TG = area under the curve for TG.
increase in HDL cholesterol was signiﬁcantly greater with
pioglitazone therapy compared with rosiglitazone therapy
(14.9% and 7.8%, resp.). Again, there was a diﬀerence in
HDL particle subclasses between the medications. Pioglita-
zoneincreasedtotal,large,andmediumHDLswhiledecreas-
ing small HDL concentration. Rosiglitazone, in contrast,
decreased total, large, and small HDLs while increasing
medium HDL particle concentration. These suggest that
there are diﬀerences in HDL metabolism with these two
agents. Pioglitazone had no eﬀect on serum apolipoprotein
AI levels, but rosiglitazone therapy was associated with a
decrease in apolipoprotein AI levels.
3.2. Thiazolidinedionesasmonotherapy:effectson
postprandiallipemia
Postprandial dyslipidemia is a feature of type 2 diabetes.
Two small studies compared the eﬀects of pioglitazone and
rosiglitazone on postprandial lipemia using a prospective,
randomized crossover design [14, 15]. After washing out
both glucose-lowering (8 weeks) and lipid-altering med-
ications (4 weeks), patients were randomized to either
pioglitazone (30mg QD for 4 weeks, then 45mg QD for 8
weeks) or rosiglitazone (4mg QD for 4 weeks followed by
4mg bid for 8 weeks) with an 8-week washout during the
crossover. Before and after each treatment, a standardized
breakfast was served and postprandial glucose, lipids, and
hormones were measured.
Both agents had similar eﬀects on A1c and HOMA-IR.
Pioglitazone reduced fasting and postprandial triglycerides
that were associated with decreases in the smaller VLDL
subfractions: VLDL-2 and VLDL-3. Rosiglitazone increased
the postprandial triglycerides with increases in VLDL-2
and VLDL-3. There was no eﬀect with either medication
on fasting apolipoprotein B, AI, or CII/CIII ratio, and
lipoprotein lipase or hepatic lipase activity did not diﬀer
between therapies. Cholesterol ester transfer protein activity
decreased with rosiglitazone and increased after pioglitazone
therapy. The second study demonstrated that pioglitazone
was more eﬀective than rosiglitazone in increasing larger
LDL concentrations (fasting and postprandial) as well as in
reducing levels of small, dense LDL particles [14].
3.3. Thiazolidinedionesincombinationwithotheroral
antihyperglycemicmedications
Derosa et al. [16] compared the eﬀect of adding pioglita-
zone (15mg QD) or rosiglitazone (4mg QD) on patients
with type 2 diabetes treated with glimepiride (4mg QD).
After 12 months, both groups had signiﬁcant reductions
in A1c (1.3%). The group treated with the pioglitazone
combination had a reduction in total cholesterol, LDL
cholesterol, lipoprotein (a), and apolipoprotein B with an
increase in HDL cholesterol. The rosiglitazone group had
increases in total cholesterol, LDL cholesterol, triglycerides,
and apolipoprotein B but no eﬀect on HDL cholesterol or4 PPAR Research
lipoprotein (a) [17]. Both groups showed a reduction in
homocysteine.
In a similarly designed trial, patients with type 2
diabetes were treated with metformin and randomized to
pioglitazone or rosiglitazone [18]. After 12 months, both
groups had similar reductions in A1c and insulin resis-
tance (as determined by HOMA-IR). Total cholesterol, LDL
cholesterol, triglycerides, and apolipoprotein B decreased in
thepioglitazonegroupwithincreasesinHDLcholesteroland
apolipoprotein AI. There were no changes observed in the
rosiglitazone group.
3.4. Thiazolidinedionesincombinationwithstatins
Berhanu et al. [19] examined the changes in lipids when
patients were switched from rosiglitazone and a statin to
pioglitazone (30mg) while maintaining a stable statin dose.
At the end of the trial (17 weeks), although the A1c did
not change, patients had a signiﬁcant reduction in triglyc-
erides, total cholesterol, and LDL particle concentration
(189nmol/L) and increases in LDL cholesterol, HDL choles-
terol, and LDL particle diameter (0.23nm). Apolipoprotein
B did not change but apolipoprotein AI increased.
In summary, although the head-to-head and
rosiglitazone-only [20] clinical trials demonstrate a beneﬁt
of rosiglitazone on HDL cholesterol, there isa relatively
consistent and overall favorable impact of pioglitazone
compared to rosiglitazone on serum lipids, lipoproteins,
and apolipoproteins. It is also clear that the lipids’ eﬀects
are unrelated to the changes in insulin sensitivity since [1]
both agents have similar eﬀects to improve insulin sensitivity
and [2] the eﬀect on insulin sensitivity can be clearly
diﬀerentiated from lipid changes [21]. Thus, there must be
other diﬀerences in the action of the thiazolidinediones that
account for the divergent lipid eﬀects.
3.5. Comparisonofmechanismsof
actiononlipidmetabolism
Whole-body fatty acid/triglyceride metabolism involves the
interaction of numerous organs as described above. Since
both pioglitazone and rosiglitazone have similar eﬀects in
the adipocyte on adipokines’ expression and genes involved
in fatty acid/triglyceride metabolism, the diﬀerence between
these medications on serum triglycerides likely occurs within
the liver and/or plasma compartment.
Themostprofounddiﬀerencebetweenthelipideﬀectsof
pioglitazone versus rosiglitazone is in fasting and postpran-
dial triglycerides. As both medications have similar eﬀectson
glycemic control and insulin resistance, an additional mech-
anism must account for these diﬀerences. The diﬀerences in
serum triglycerides occur in smaller VLDL particles which
are produced in an insulin-independent fashion consistent
with the observations that it is not the change in insulin
resistance that accounts for the diﬀerences. One potential
diﬀerence, which may account for the diﬀerence, is the eﬀect
on apolipoprotein CIII. Two studies have demonstrated
that pioglitazone decreases and rosiglitazone increases
apolipoprotein CIII [10, 22]. A decrease in apolipoprotein
CIII would lead to an increase in lipoprotein lipase activity,
and hence an increase in the hydrolysis of triglycerides
and catabolic rate of triglyceride-rich lipoproteins including
chylomicrons and VLDL [23]. This hypothesis is supported
by the observation that pioglitazone increases the lipolysis
of VLDL triglycerides without aﬀecting the removal of
VLDL particles [22]. Conversely, rosiglitazone increases the
production and reduces the catabolism of triglyceride-rich
lipoproteins including both VLDL and chylomicrons [21].
Another possibility is that genetic diﬀerences may con-
tribute to the diﬀerent lipid eﬀects. Polymorphism of the
PPARγ2 gene inﬂuences the glycemic response to rosiglita-
zone [24] but not to pioglitazone [25]. A lipoprotein lipase
variant inﬂuences the glycemic eﬀect of pioglitazone [26],
while a polymorphism of the adiponectin [27] and perilipin
[28]genesinﬂuencestheglycemicandweightgainresponses,
respectively, to rosiglitazone. Since none of these studies
directly compared both rosiglitazone and pioglitazone, it
is unclear if polymorphism contributes to the diﬀerences.
Most of these studies also did not show a linkage between
lipid eﬀects and polymorphisms, but a link between the
adiponectin genotype at position 45 and the triglyceride
eﬀect of rosiglitazone did statistically approach signiﬁcance
[27]. Whether this occurs with pioglitazone has not been
published to date.
It is possible that pharmacokinetic diﬀerences between
pioglitazone and rosiglitazone may account for the diﬀer-
ences in lipid eﬀects; however, this is an unlikely contributor
since the gene expression and pharmacodynamic eﬀects of
both agents exceed the presence of active drug in the serum.
Do the diﬀerences in lipid eﬀects have clinical signiﬁ-
cance? Increased fasting and postprandial triglycerides [29,
30] as well as LDL particle concentration [12, 13]a r er i s k
factors for cardiovascular disease. Conversely, increases in
large HDL and adiponectin are associated with reduction
in risk. It is also likely that other eﬀects inﬂuence the
risk of coronary artery disease (CAD) events. It is likely
that the integrated sum of these lipid eﬀects, together
with yet-deﬁned factors, will determine the inﬂuence on
atherosclerosis.
Clinical outcome trials with both pioglitazone and
rosiglitazone have been published. Both pioglitazone and
rosiglitazone improve endothelial function and reduce the
progression of carotid intramedial thickness in patients [31–
34]. These observations suggest a clinical beneﬁt with both
agents. In the PROACTIVE study, adding pioglitazone to
the current treatment in patients with type 2 diabetes was
associated with reductions in major atherosclerotic events
as deﬁned in the main secondary end-point [35], recurrent
myocardial infarction [36], and recurrent stroke [37]. Meta-
analysis of pioglitazone clinical trials showed a signiﬁcantly
lower risk of death, myocardial infarction, or stroke in
patients with diabetes [20].
The eﬀect of rosiglitazone on CAD events is more
controversial. Some post hoc meta-analysis studies have
suggested that rosiglitazone is associated with an increased
riskofCADevents[38,39].However,intheRECORDtrial,a
prospective trial in patients with type 2 diabetes, no evidence
for an increased event rate was found in an interim analysisM .A .D e e ga n dM .H .T a n 5
[40]. Completion of this along with other studies is needed
to fully answer the eﬀect of rosiglitazone on CAD events.
4. SUMMARY
Both pioglitazone and rosiglitazone reduce insulin resistance
and improve glycemic control in patients with type 2 dia-
betes. However, the head-to-head clinical trials demonstrate
a relatively consistent and favorable impact of pioglitazone
compared to rosiglitazone on serum lipids, lipoproteins,
and apolipoproteins. Whether these diﬀerences result in
diﬀerent outcomes that are clinically signiﬁcant remains to
be determined.
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